UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Rituximab in Membranous Nephropathy

Gauckler, P; Shin, JI; Alberici, F; Audard, V; Bruchfeld, A; Busch, M; Cheung, CK; ... Kronbichler, A; + view all (2021) Rituximab in Membranous Nephropathy. Kidney International Reports 10.1016/j.ekir.2020.12.035. (In press). Green open access

[img]
Preview
Text
Salama_Rituximab in Membranous Nephropathy_AOP.pdf - Published version

Download (713kB) | Preview

Abstract

Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard.”

Type: Article
Title: Rituximab in Membranous Nephropathy
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ekir.2020.12.035
Publisher version: http://dx.doi.org/10.1016/j.ekir.2020.12.035
Language: English
Additional information: © 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: B cells, membranous nephropathy, nephrotic syndrome, rituximab
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10125429
Downloads since deposit
4Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item